Alamar Q2 revenue $29.4M (+82% YoY); guides FY26 to $116-120M

Alamar Biosciences, Inc.

Q2 revenue $29.4M, up 82% from $16.2M YoY; consumables +147% to $15.5M, instruments +35% to $7.8M.
Gross margin improved to 60% vs 53% YoY; operating loss widened to $13.5M from $7.9M.
Net loss $13.2M vs $7.0M YoY; cash and investments $256.3M at June 30, 2026.
FY2026 revenue guidance raised to $116-120M, ~59% growth at midpoint vs 2025.
Launched eMTBR-tau blood assay and NULISAseq Immune 340 Panel; expanded Alzheimer's partnership with Gates Ventures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.